These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmaceutical company sponsored disease management programs: an alternative for tax-exempt MCOs and hospitals. Jedrey CM; Chaurette KA; Winn LB Manag Care Q; 2002; 10(3):11-5. PubMed ID: 12476660 [TBL] [Abstract][Full Text] [Related]
4. Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs. Simmer WS Manag Care Interface; 2002 Jan; 15(1):90-2. PubMed ID: 11828611 [TBL] [Abstract][Full Text] [Related]
5. How well does your PBM perform? McCarthy R Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211 [No Abstract] [Full Text] [Related]
6. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation. Benko LB Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517 [No Abstract] [Full Text] [Related]
7. PBMs: ripe for regulation. Johnson RS Food Drug Law J; 2002; 57(2):323-69. PubMed ID: 12437004 [No Abstract] [Full Text] [Related]
8. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach. Kuhlik BN Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984 [No Abstract] [Full Text] [Related]
14. Off-label or off-limits? Ratner M; Gura T Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236 [No Abstract] [Full Text] [Related]
15. The spotlight on PBMs: federal enforcement of the anti-kickback statute on the pharmaceutical benefit management industry. Radinsky G J Health Law; 2003; 36(2):213-46. PubMed ID: 12940677 [TBL] [Abstract][Full Text] [Related]
16. Doctor explains why he blew the whistle. Petersen M N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161 [No Abstract] [Full Text] [Related]
17. The response to health care reform by the pharmaceutical industry. Krulwich AS Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983 [No Abstract] [Full Text] [Related]
18. Pharmaceutical industry and payer partnerships to manage costs and improve quality. Mauch RP Manag Care; 2001 Sep; 10(9 Suppl):2-4; discussion 9-12. PubMed ID: 11729438 [No Abstract] [Full Text] [Related]
19. Disease state management: who should pay? Kozma CM Med Interface; 1997 Feb; 10(2):96-7. PubMed ID: 10164798 [No Abstract] [Full Text] [Related]
20. Implications for managed care organizations of the Merck and Medco consent. Pollard MR; Tilson HH Med Interface; 1996 Mar; 9(3):60-2. PubMed ID: 10184511 [No Abstract] [Full Text] [Related] [Next] [New Search]